Geoff Meacham
Stock Analyst at Citigroup
(4.42)
# 326
Out of 5,090 analysts
279
Total ratings
61.71%
Success rate
13.87%
Average return
Main Sectors:
Stocks Rated by Geoff Meacham
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Maintains: Buy | $58 → $49 | $16.28 | +200.98% | 3 | Dec 2, 2025 | |
| PFE Pfizer | Reinstates: Neutral | $26 | $25.89 | +0.42% | 7 | Dec 2, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $9 → $8 | $1.94 | +313.44% | 6 | Nov 18, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $96 → $98 | $88.27 | +11.02% | 3 | Nov 10, 2025 | |
| PTCT PTC Therapeutics | Maintains: Neutral | $50 → $75 | $76.82 | -2.37% | 10 | Nov 5, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $240 → $235 | $225.39 | +4.26% | 21 | Nov 3, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $660 → $700 | $719.68 | -2.73% | 24 | Oct 29, 2025 | |
| RNA Avidity Biosciences | Downgrades: Neutral | $75 → $72 | $71.67 | +0.46% | 8 | Oct 27, 2025 | |
| MRNA Moderna | Maintains: Neutral | $30 → $28 | $26.70 | +4.87% | 11 | Oct 23, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Buy | $42 → $50 | $34.98 | +42.94% | 2 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $80 | $65.04 | +23.00% | 6 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $50 | $41.04 | +21.83% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $20 | $14.58 | +37.17% | 5 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $93 | $57.76 | +61.01% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $84 → $95 | $100.22 | -5.21% | 8 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $135 | $120.57 | +11.97% | 7 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $575 | $456.40 | +25.99% | 6 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $14 | $6.25 | +124.18% | 3 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $305 → $310 | $331.50 | -6.49% | 13 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $125 → $135 | $181.75 | -25.72% | 15 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $42 | $39.16 | +7.25% | 3 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $54 | $72.41 | -25.42% | 6 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $67.58 | +62.77% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $6 | $6.78 | -11.50% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $145 → $140 | $96.19 | +45.55% | 2 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $1 | $2.25 | -55.56% | 3 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $95 | $75.29 | +26.18% | 2 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $99 → $103 | $53.20 | +93.61% | 3 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $112 → $4 | $2.12 | +88.68% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,150 → $1,100 | $1,013.40 | +8.55% | 9 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $120 → $20 | $25.20 | -20.63% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $22 → $31 | $22.18 | +39.80% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $170 | $201.25 | -15.53% | 3 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $68 → $60 | $52.40 | +14.50% | 8 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $10 → $8 | $5.13 | +55.95% | 4 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $17 | $1.63 | +943.39% | 1 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $24 | $2.00 | +1,100.00% | 4 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $4 | $10.76 | -62.83% | 2 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $3.19 | +777.74% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $0.52 | +6,444.75% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $35 | $3.75 | +833.33% | 4 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $525 | $23.77 | +2,108.67% | 1 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $1.25 | +3,260.00% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $8.58 | +133.10% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $0.51 | +3,813.13% | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underperform | $9 | $5.25 | +71.43% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $12.90 | +365.12% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $23 | $26.14 | -12.01% | 3 | Aug 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $90 → $82 | $101.34 | -19.08% | 9 | May 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $95 | $481.78 | -80.28% | 6 | Mar 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $300 → $80 | $13.05 | +513.03% | 3 | Dec 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $135 | $155.77 | -13.33% | 2 | Aug 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $11.10 | - | 4 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $3.46 | +478.03% | 4 | May 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $9.38 | - | 2 | Apr 5, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $158 | $456.68 | -65.40% | 5 | Nov 8, 2017 |
Janux Therapeutics
Dec 2, 2025
Maintains: Buy
Price Target: $58 → $49
Current: $16.28
Upside: +200.98%
Pfizer
Dec 2, 2025
Reinstates: Neutral
Price Target: $26
Current: $25.89
Upside: +0.42%
Acumen Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $1.94
Upside: +313.44%
Protagonist Therapeutics
Nov 10, 2025
Maintains: Buy
Price Target: $96 → $98
Current: $88.27
Upside: +11.02%
PTC Therapeutics
Nov 5, 2025
Maintains: Neutral
Price Target: $50 → $75
Current: $76.82
Upside: -2.37%
AbbVie
Nov 3, 2025
Maintains: Neutral
Price Target: $240 → $235
Current: $225.39
Upside: +4.26%
Regeneron Pharmaceuticals
Oct 29, 2025
Maintains: Buy
Price Target: $660 → $700
Current: $719.68
Upside: -2.73%
Avidity Biosciences
Oct 27, 2025
Downgrades: Neutral
Price Target: $75 → $72
Current: $71.67
Upside: +0.46%
Moderna
Oct 23, 2025
Maintains: Neutral
Price Target: $30 → $28
Current: $26.70
Upside: +4.87%
NewAmsterdam Pharma Company
Oct 17, 2025
Maintains: Buy
Price Target: $42 → $50
Current: $34.98
Upside: +42.94%
Oct 17, 2025
Maintains: Buy
Price Target: $60 → $80
Current: $65.04
Upside: +23.00%
Oct 17, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $41.04
Upside: +21.83%
Oct 17, 2025
Maintains: Buy
Price Target: $12 → $20
Current: $14.58
Upside: +37.17%
Oct 17, 2025
Maintains: Buy
Price Target: $78 → $93
Current: $57.76
Upside: +61.01%
Oct 13, 2025
Reinstates: Neutral
Price Target: $84 → $95
Current: $100.22
Upside: -5.21%
Oct 8, 2025
Maintains: Buy
Price Target: $125 → $135
Current: $120.57
Upside: +11.97%
Oct 2, 2025
Maintains: Buy
Price Target: $550 → $575
Current: $456.40
Upside: +25.99%
Aug 27, 2025
Upgrades: Buy
Price Target: $12 → $14
Current: $6.25
Upside: +124.18%
Aug 6, 2025
Maintains: Neutral
Price Target: $305 → $310
Current: $331.50
Upside: -6.49%
Aug 1, 2025
Maintains: Neutral
Price Target: $125 → $135
Current: $181.75
Upside: -25.72%
Jul 22, 2025
Maintains: Buy
Price Target: $40 → $42
Current: $39.16
Upside: +7.25%
Jun 25, 2025
Maintains: Buy
Price Target: $50 → $54
Current: $72.41
Upside: -25.42%
Jun 17, 2025
Initiates: Buy
Price Target: $110
Current: $67.58
Upside: +62.77%
Jun 17, 2025
Initiates: Sell
Price Target: $6
Current: $6.78
Upside: -11.50%
May 6, 2025
Maintains: Buy
Price Target: $145 → $140
Current: $96.19
Upside: +45.55%
Apr 2, 2025
Downgrades: Underperform
Price Target: $7 → $1
Current: $2.25
Upside: -55.56%
Mar 13, 2025
Initiates: Buy
Price Target: $95
Current: $75.29
Upside: +26.18%
Feb 20, 2025
Maintains: Buy
Price Target: $99 → $103
Current: $53.20
Upside: +93.61%
Jan 7, 2025
Downgrades: Underperform
Price Target: $112 → $4
Current: $2.12
Upside: +88.68%
Oct 31, 2024
Maintains: Buy
Price Target: $1,150 → $1,100
Current: $1,013.40
Upside: +8.55%
Oct 30, 2024
Downgrades: Underperform
Price Target: $120 → $20
Current: $25.20
Upside: -20.63%
Oct 18, 2024
Upgrades: Buy
Price Target: $22 → $31
Current: $22.18
Upside: +39.80%
Apr 17, 2024
Maintains: Neutral
Price Target: $180 → $170
Current: $201.25
Upside: -15.53%
Jan 3, 2024
Downgrades: Neutral
Price Target: $68 → $60
Current: $52.40
Upside: +14.50%
Aug 21, 2023
Maintains: Underperform
Price Target: $10 → $8
Current: $5.13
Upside: +55.95%
Aug 21, 2023
Maintains: Buy
Price Target: $19 → $17
Current: $1.63
Upside: +943.39%
Nov 1, 2022
Downgrades: Underperform
Price Target: $24
Current: $2.00
Upside: +1,100.00%
Jun 8, 2022
Downgrades: Neutral
Price Target: $12 → $4
Current: $10.76
Upside: -62.83%
Aug 10, 2021
Initiates: Buy
Price Target: $28
Current: $3.19
Upside: +777.74%
Jul 13, 2021
Initiates: Buy
Price Target: $34
Current: $0.52
Upside: +6,444.75%
Jan 15, 2021
Downgrades: Neutral
Price Target: $35
Current: $3.75
Upside: +833.33%
Nov 23, 2020
Initiates: Buy
Price Target: $525
Current: $23.77
Upside: +2,108.67%
Oct 20, 2020
Initiates: Buy
Price Target: $42
Current: $1.25
Upside: +3,260.00%
Sep 15, 2020
Reinstates: Buy
Price Target: $20
Current: $8.58
Upside: +133.10%
Sep 8, 2020
Reinstates: Buy
Price Target: $20
Current: $0.51
Upside: +3,813.13%
Jun 25, 2020
Reinstates: Underperform
Price Target: $9
Current: $5.25
Upside: +71.43%
Jun 25, 2020
Reinstates: Buy
Price Target: $60
Current: $12.90
Upside: +365.12%
Aug 5, 2019
Maintains: Equal-Weight
Price Target: $15 → $23
Current: $26.14
Upside: -12.01%
May 3, 2019
Downgrades: Equal-Weight
Price Target: $90 → $82
Current: $101.34
Upside: -19.08%
Mar 1, 2019
Maintains: Underweight
Price Target: $100 → $95
Current: $481.78
Upside: -80.28%
Dec 20, 2018
Downgrades: Equal-Weight
Price Target: $300 → $80
Current: $13.05
Upside: +513.03%
Aug 1, 2018
Maintains: Overweight
Price Target: $100 → $135
Current: $155.77
Upside: -13.33%
May 21, 2018
Downgrades: Underweight
Price Target: n/a
Current: $11.10
Upside: -
May 3, 2018
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $3.46
Upside: +478.03%
Apr 5, 2018
Downgrades: Equal-Weight
Price Target: n/a
Current: $9.38
Upside: -
Nov 8, 2017
Maintains: Overweight
Price Target: $127 → $158
Current: $456.68
Upside: -65.40%